ReviewMedicine and pharmacy reports2022
Current approaches in the management of patients with keratoconus.
Review in Medicine and pharmacy reports, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed, 1 synthesis or guideline pooled it, 4 citations in OpenAlex.
- Lenticule addition keratoplasty for the treatment of keratoconus: A systematic review and critical considerations.Indian journal of ophthalmology · 2024Pooled it
- Paediatric Keratoconus: An ERN-EYE Clinical Consensus Statement on Diagnosis, Treatment and Follow-Up Care.Ophthalmology and therapy · 2026Review
- Deep-stromal implantation of a double-crosslinked bioengineered porcine collagen implant (BPCDX) in advanced keratoconus: a 12-month study of corneal remodeling and visual outcomes.Scientific reports · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Keratoconus is a relatively frequent eye disease, especially in young patients, in which the cornea gradually thins and deforms in a cone shape. In the past, it could be treated only with glasses, rigid contact lenses or, for advanced cases, penetrating corneal transplant. Nowadays, corneal cross-linking, intracorneal ring segments implantation or deep anterior lamellar keratoplasty are available options of treatment, along with the above mentioned ones. Several studies focused on this disease and its management attempted to establish the applicability of these treatment methods in current practice. In the early stages, glasses or soft toric contact lenses are able to correct the astigmatism, but, as the disease progresses, rigid contact lenses are indicated. Corneal cross-linking is done in order to slow down or even stop the progression of the disease. Implanting intracorneal ring segments helps improve visual acuity in patients with low vision that cannot be corrected otherwise. Advanced stages need corneal transplant, either penetrating or anterior lamellar, depending on each patient's ocular characteristics. Thus, keratoconus treatment is individualized for every patient, according to the stage of the disease. Moreover, because of the new developed technology, keratoconus patients can benefit from efficient treatment, in much safer conditions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.